Search research articles
Contact Us
Filters
Showing results (31-40 of 303) with videos related to
Page
of 31
Sort By:
Oncology (Williston Park, N.Y.)
|
August 17, 2005
Antiangiogenic therapy in cancer: a new era has begun
Axel Grothey
Clinical Advances in Hematology & Oncology : H&O
|
April 12, 2021
The importance of keeping patients with metastatic colorectal cancer on treatment through the management of adverse events
Axel Grothey
Clinical Advances in Hematology & Oncology : H&O
|
July 29, 2020
Insights Into the Mechanism of Action of Regorafenib in Colorectal Cancer
Axel Grothey
Clinical Colorectal Cancer
|
January 24, 2007
Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial
Preeta Tyagi, Axel Grothey
Oncotargets and Therapy
|
October 29, 2015
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
Yiyi Yan, Axel Grothey
Expert Review of Anticancer Therapy
|
November 27, 2012
Treatment options for advanced pancreatic cancer: a review
Rahma Warsame, Axel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2005
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line
Axel Grothey, Daniel Sargent
JAMA Network Open
|
October 30, 2023
Improving Rectal Cancer Treatments 1 Study at a Time
Noam VanderWalde, Axel Grothey
Therapeutic Advances in Medical Oncology
|
November 3, 2012
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer
Axel Grothey, Carmen Allegra
Expert Opinion on Pharmacotherapy
|
November 13, 2015
Regorafenib in the treatment of colorectal cancer
Neil Majithia, Axel Grothey
Page
of 31
Search research articles
Search
Showing results (31-40 of 303) with videos related to
Sort By:
Page
of 31
Oncology (Williston Park, N.Y.)
|
August 17, 2005
Antiangiogenic therapy in cancer: a new era has begun
Axel Grothey
Clinical Advances in Hematology & Oncology : H&O
|
April 12, 2021
The importance of keeping patients with metastatic colorectal cancer on treatment through the management of adverse events
Axel Grothey
Clinical Advances in Hematology & Oncology : H&O
|
July 29, 2020
Insights Into the Mechanism of Action of Regorafenib in Colorectal Cancer
Axel Grothey
Clinical Colorectal Cancer
|
January 24, 2007
Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial
Preeta Tyagi, Axel Grothey
Oncotargets and Therapy
|
October 29, 2015
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
Yiyi Yan, Axel Grothey
Expert Review of Anticancer Therapy
|
November 27, 2012
Treatment options for advanced pancreatic cancer: a review
Rahma Warsame, Axel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2005
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line
Axel Grothey, Daniel Sargent
JAMA Network Open
|
October 30, 2023
Improving Rectal Cancer Treatments 1 Study at a Time
Noam VanderWalde, Axel Grothey
Therapeutic Advances in Medical Oncology
|
November 3, 2012
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer
Axel Grothey, Carmen Allegra
Expert Opinion on Pharmacotherapy
|
November 13, 2015
Regorafenib in the treatment of colorectal cancer
Neil Majithia, Axel Grothey
Page
of 31